Switch theme
Sign up to access all valuation multiples
PT Industri Jamu dan Farmasi Sido Muncul Tbk is biotechnology company that provides herbal medicine and pharmaceutical products. The company has three business segments, Herbal Medicine and supplement, Food and Beverage, and Pharmacy. The Herbal Medicine segment provides herbal supplements, while its Food and Beverage segment sells packaged foods, soft drinks, and candy and confectionary products. The Pharmacy segment sells pharmaceutical products such as Anacetine, a fever reducer, Berlosid, a medicine to reduce gastric pain, and Combicitrine, a medicine for bacterial removal. The company generates the majority of its revenue in Indonesia.
1975
4.4K+
LTM Revenue $250M
LTM EBITDA $95.7M
$876M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sido Muncul has a last 12-month revenue (LTM) of $250M and a last 12-month EBITDA of $95.7M.
In the most recent fiscal year, Sido Muncul achieved revenue of $240M and an EBITDA of $93.4M.
Sido Muncul expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sido Muncul valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $250M | XXX | $240M | XXX | XXX | XXX |
| Gross Profit | $148M | XXX | $141M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $95.7M | XXX | $93.4M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 39% | XXX | XXX | XXX |
| EBIT | $90.8M | XXX | $90.4M | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 38% | XXX | XXX | XXX |
| Net Profit | $72.2M | XXX | $71.8M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sido Muncul's stock price is IDR 515 (or $0).
Sido Muncul has current market cap of IDR 15.45T (or $948M), and EV of IDR 14.28T (or $876M).
See Sido Muncul trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $876M | $948M | XXX | XXX | XXX | XXX | $0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sido Muncul has market cap of $948M and EV of $876M.
Sido Muncul's trades at 3.6x EV/Revenue multiple, and 9.4x EV/EBITDA.
Equity research analysts estimate Sido Muncul's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sido Muncul has a P/E ratio of 13.1x.
See valuation multiples for Sido Muncul and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $948M | XXX | $948M | XXX | XXX | XXX |
| EV (current) | $876M | XXX | $876M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | 9.7x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.1x | XXX | 13.2x | XXX | XXX | XXX |
| EV/FCF | 13.3x | XXX | 12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSido Muncul's last 12 month revenue growth is 6%
Sido Muncul's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $12K for the same period.
Sido Muncul's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sido Muncul's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sido Muncul and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $12K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sido Muncul acquired XXX companies to date.
Last acquisition by Sido Muncul was XXXXXXXX, XXXXX XXXXX XXXXXX . Sido Muncul acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sido Muncul founded? | Sido Muncul was founded in 1975. |
| Where is Sido Muncul headquartered? | Sido Muncul is headquartered in Indonesia. |
| How many employees does Sido Muncul have? | As of today, Sido Muncul has 4.4K+ employees. |
| Is Sido Muncul publicy listed? | Yes, Sido Muncul is a public company listed on IDX. |
| What is the stock symbol of Sido Muncul? | Sido Muncul trades under SIDO ticker. |
| When did Sido Muncul go public? | Sido Muncul went public in 2013. |
| Who are competitors of Sido Muncul? | Similar companies to Sido Muncul include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Sido Muncul? | Sido Muncul's current market cap is $948M |
| What is the current revenue of Sido Muncul? | Sido Muncul's last 12 months revenue is $250M. |
| What is the current revenue growth of Sido Muncul? | Sido Muncul revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Sido Muncul? | Current revenue multiple of Sido Muncul is 3.5x. |
| Is Sido Muncul profitable? | Yes, Sido Muncul is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sido Muncul? | Sido Muncul's last 12 months EBITDA is $95.7M. |
| What is Sido Muncul's EBITDA margin? | Sido Muncul's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Sido Muncul? | Current EBITDA multiple of Sido Muncul is 9.1x. |
| What is the current FCF of Sido Muncul? | Sido Muncul's last 12 months FCF is $65.7M. |
| What is Sido Muncul's FCF margin? | Sido Muncul's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Sido Muncul? | Current FCF multiple of Sido Muncul is 13.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
